You can tell the competency of your doctor and stroke hospital if they know about this and have in place procedures to notify every stroke survivor they ever treated when results come out. I wouldn't hold my breath. Your doctor needs to see if their definition of cardiovascular disease includes strokes. If so this research doesn't help stroke survivors one bit.
Could taking statins prevent dementia, disability?
NIH-funded clinical trial will test statins in 20,000 older adults
The National Institute on Aging (NIA) has funded a major study to
examine the overall benefits and risks of cholesterol-lowering drugs
known as statins in adults age 75 or older without cardiovascular
disease. The trial will help determine whether a statin can help prevent
dementia and disability in this age group, as well as heart attacks and
other cardiovascular-related deaths, while not increasing risks of
adverse health outcomes. Funding for the trial, called Pragmatic
Evaluation of Events and Benefits of Lipid-Lowering in Older Adults
(PREVENTABLE), is expected to total $90 million over the next seven
years. NIA is part of the National Institutes of Health.
"There
has been considerable uncertainty about the benefits and risks of
statin use in persons over age 75 years without known cardiovascular
disease,” said NIA Director Richard J. Hodes, M.D. “This large trial
with older adults in real-world clinical settings will provide the
opportunity to further our knowledge and better inform treatment
decisions for older adults.”
To date, no large prospective studies have examined whether statin therapy could prevent cardiovascular events specifically in adults older than age 75 who do not have clinical cardiovascular disease. In addition, previous studies enrolled small numbers of people at risk for cognitive impairment so the potential effect of statins on dementia—either preventing or worsening it—could not be established.
Participants will be enrolled from 60 hospitals and 40 health care systems that are part of clinical trial networks supported by the U.S. Department of Veterans Affairs and the National Patient-Centered Clinical Research Network. The investigators will enroll 20,000 participants without signs of heart disease but who may be frail, take multiple medications and have mild cognitive impairment. Each participant will be randomly assigned to take either the statin atorvastatin or a placebo daily for up to five years.
“Because of the large size of this study, we may be able to identify subgroups of older adults most likely to benefit from taking statins to prevent dementia, disability or cardiovascular disease,” said Susan Zieman, M.D., Ph.D., medical officer in NIA’s Division of Geriatrics and Clinical Gerontology. “The large, diverse study population will also enable us to better evaluate unwanted effects of statins that may put some at risk or reduce their quality of life.”
Four co-principal investigators will lead the PREVENTABLE trial: Karen P. Alexander, M.D. and Adrian Hernandez, M.D. at Duke University Medical Center, Durham, North Carolina; and Jeff D. Williamson, M.D. and Walter T. Ambrosius, Ph.D. at Wake Forest School of Medicine, Winston-Salem, North Carolina.
The trial is funded by NIA grant U19AG065188. Starting in Fiscal Year 2021, the trial will have additional support from the NIH National Heart, Lung, and Blood Institute (NHLBI).
"There
has been considerable uncertainty about the benefits and risks of
statin use in persons over age 75 years without known cardiovascular
disease,” said NIA Director Richard J. Hodes, M.D. “This large trial
with older adults in real-world clinical settings will provide the
opportunity to further our knowledge and better inform treatment
decisions for older adults.”To date, no large prospective studies have examined whether statin therapy could prevent cardiovascular events specifically in adults older than age 75 who do not have clinical cardiovascular disease. In addition, previous studies enrolled small numbers of people at risk for cognitive impairment so the potential effect of statins on dementia—either preventing or worsening it—could not be established.
Participants will be enrolled from 60 hospitals and 40 health care systems that are part of clinical trial networks supported by the U.S. Department of Veterans Affairs and the National Patient-Centered Clinical Research Network. The investigators will enroll 20,000 participants without signs of heart disease but who may be frail, take multiple medications and have mild cognitive impairment. Each participant will be randomly assigned to take either the statin atorvastatin or a placebo daily for up to five years.
“Because of the large size of this study, we may be able to identify subgroups of older adults most likely to benefit from taking statins to prevent dementia, disability or cardiovascular disease,” said Susan Zieman, M.D., Ph.D., medical officer in NIA’s Division of Geriatrics and Clinical Gerontology. “The large, diverse study population will also enable us to better evaluate unwanted effects of statins that may put some at risk or reduce their quality of life.”
Four co-principal investigators will lead the PREVENTABLE trial: Karen P. Alexander, M.D. and Adrian Hernandez, M.D. at Duke University Medical Center, Durham, North Carolina; and Jeff D. Williamson, M.D. and Walter T. Ambrosius, Ph.D. at Wake Forest School of Medicine, Winston-Salem, North Carolina.
The trial is funded by NIA grant U19AG065188. Starting in Fiscal Year 2021, the trial will have additional support from the NIH National Heart, Lung, and Blood Institute (NHLBI).
No comments:
Post a Comment